Dr. Macey studies various conditions affecting blood health, particularly different types of leukemia including acute myeloid leukemia (AML), chronic neutrophilic leukemia (CNL), and atypical chronic myeloid leukemia (aCML). He investigates how these conditions respond to specific treatments, such as the drug ruxolitinib, and the genetic factors that can predict patient outcomes. Additionally, he explores the patterns of opioid use in veterans with persistent pain, identifying who is more likely to require long-term opioid therapy. His research aims to improve treatment strategies and outcomes for these patients.
Key findings
In AML, a single gene, PEAR1, was identified as a strong predictor of survival, especially among younger patients from a study of 805 patients.
In a study of 44 patients with CNL and aCML, 35% responded positively to ruxolitinib, with some achieving complete recovery.
Researchers identified new mutations in AML through the genetic analysis of 562 patients, leading to better understanding of drug responses and potential treatment options.
In a study of nearly 6,000 veterans, 35% received an opioid prescription, with only 5% continuing for more than 90 days; younger veterans with higher pain levels were more likely to need long-term opioids.
Parenting difficulties were linked to a significantly higher chance of asthma development in genetically at-risk children, based on observations of 150 children.
Frequently asked questions
Does Dr. Macey study leukemia?
Yes, Dr. Macey studies different types of leukemia, particularly acute myeloid leukemia, and explores treatment options and genetic factors related to these cancers.
What treatments has Dr. Macey researched?
Dr. Macey has researched the effectiveness of ruxolitinib for chronic neutrophilic leukemia and atypical chronic myeloid leukemia, among other treatments for blood cancers.
Is Dr. Macey's work relevant to veterans?
Yes, Dr. Macey's research on opioid use in veterans with persistent pain is highly relevant, as it identifies factors that affect long-term opioid prescriptions.
Can Dr. Macey's research help my child with asthma?
Yes, Dr. Macey's research looking at early parenting issues and asthma development can provide insights for parents of at-risk children.
What is the significance of the PEAR1 gene in leukemia?
The PEAR1 gene has been identified as a strong predictor of survival in patients with acute myeloid leukemia, particularly benefiting younger patients.
Publications in plain English
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.
2022
Cancer cell
Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE +89 more
Plain English This study looked at how acute myeloid leukemia (AML) responds to different drugs and how these responses relate to patient outcomes. Researchers analyzed data from 805 AML patients and found that the way cancer cells differentiate affects their sensitivity to treatment. They also identified a gene called PEAR1 as a key indicator of survival, particularly in younger patients, suggesting that targeting this gene could improve treatment strategies.
Who this helps: This information benefits patients with AML and their doctors by providing insights for better treatment options and predictions about survival.
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
2020
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE +21 more
Plain English This study looked at how effective the drug ruxolitinib is for patients with chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). Out of 44 patients tested, 35% responded positively to the treatment with some showing complete recovery. The results are important because they indicate that ruxolitinib can be a safe and effective option for patients with these specific blood cancers, particularly those carrying a certain mutation.
Who this helps: This helps patients with CNL and aCML.
Functional genomic landscape of acute myeloid leukaemia.
2018
Nature
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE +83 more
Plain English This study looked at the genetic features of acute myeloid leukemia (AML) by analyzing tumor samples from 562 patients. Researchers found new mutations and associations between these mutations and how well patients respond to different drugs. They created a data resource to help doctors understand these relationships better, which could improve treatment options for AML patients.
Who this helps: This helps patients with acute myeloid leukemia and their doctors.
Correlates of prescription opioid initiation and long-term opioid use in veterans with persistent pain.
2013
The Clinical journal of pain
Dobscha SK, Morasco BJ, Duckart JP, Macey T, Deyo RA
Plain English This study examined how and why veterans with ongoing pain start taking prescription opioids and how many end up using them long-term. Out of nearly 6,000 veterans who had not received opioids in the past year, 35% were given an opioid prescription, but only 5% were prescribed opioids for more than 90 days. The research found that younger veterans with higher pain levels, as well as those with mental health and substance use issues, were more likely to receive long-term opioid therapy.
Who this helps: This information benefits veterans dealing with chronic pain, as well as the doctors who treat them.
Early asthma onset: consideration of parenting issues.
1991
Journal of the American Academy of Child and Adolescent Psychiatry
Mrazek DA, Klinnert MD, Mrazek P, Macey T
Plain English This study looked at how early parenting behaviors can influence the development of asthma in children who are already at risk due to their genes. Researchers observed 150 children and their mothers, noting parenting issues when the infants were just 3 weeks old, and then tracked the children's respiratory health over the next two years. They found that difficulties in parenting were strongly linked to a higher chance of the child developing asthma, with a significant difference in asthma development between families with parenting concerns and those without.
Who this helps: Parents of young children at risk for asthma and healthcare providers working with them.
Cristina E Tognon Kim-Hien T Dao Robert H Collins Brian J Druker Jeffrey W Tyner Daniel Bottomly Nicola Long Anna Reister Schultz Stephen E Kurtz Kara Johnson
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.